Annual EBIT:
-$463.22M-$131.19M(-39.51%)Summary
- As of today, RXRX annual earnings before interest & taxes is -$463.22 million, with the most recent change of -$131.19 million (-39.51%) on December 31, 2024.
- During the last 3 years, RXRX annual EBIT has fallen by -$279.69 million (-152.40%).
- RXRX annual EBIT is now -656.35% below its all-time high of -$61.24 million, reached on December 31, 2019.
Performance
RXRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBIT:
-$172.20M+$4.03M(+2.28%)Summary
- As of today, RXRX quarterly earnings before interest & taxes is -$172.20 million, with the most recent change of +$4.03 million (+2.28%) on September 30, 2025.
- Over the past year, RXRX quarterly EBIT has dropped by -$73.85 million (-75.08%).
- RXRX quarterly EBIT is now -845.28% below its all-time high of -$18.22 million, reached on June 30, 2020.
Performance
RXRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$723.57M-$73.85M(-11.37%)Summary
- As of today, RXRX TTM earnings before interest & taxes is -$723.57 million, with the most recent change of -$73.85 million (-11.37%) on September 30, 2025.
- Over the past year, RXRX TTM EBIT has dropped by -$319.20 million (-78.94%).
- RXRX TTM EBIT is now -3844.64% below its all-time high of -$18.34 million, reached on March 31, 2020.
Performance
RXRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RXRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -39.5% | -75.1% | -78.9% |
| 3Y3 Years | -152.4% | -175.2% | -189.8% |
| 5Y5 Years | -656.4% | -666.2% | - |
RXRX EBIT Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -152.4% | at low | -182.4% | +10.0% | -194.5% | at low |
| 5Y | 5-Year | -656.4% | at low | -464.9% | +10.0% | -916.6% | at low |
| All-Time | All-Time | -656.4% | at low | -845.3% | +10.0% | -3844.6% | at low |
RXRX EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$172.20M(+2.3%) | -$723.57M(-11.4%) |
| Jun 2025 | - | -$176.23M(+7.9%) | -$649.72M(-13.2%) |
| Mar 2025 | - | -$191.37M(-4.1%) | -$574.03M(-19.8%) |
| Dec 2024 | -$463.22M(-39.5%) | -$183.77M(-86.8%) | -$479.00M(-18.5%) |
| Sep 2024 | - | -$98.35M(+2.2%) | -$404.37M(+0.3%) |
| Jun 2024 | - | -$100.54M(-4.4%) | -$405.56M(-4.9%) |
| Mar 2024 | - | -$96.34M(+11.7%) | -$386.74M(-7.3%) |
| Dec 2023 | -$332.03M(-38.7%) | -$109.13M(-9.6%) | -$360.26M(-15.4%) |
| Sep 2023 | - | -$99.55M(-21.8%) | -$312.11M(-13.4%) |
| Jun 2023 | - | -$81.72M(-17.0%) | -$275.13M(-6.0%) |
| Mar 2023 | - | -$69.86M(-14.6%) | -$259.61M(-5.7%) |
| Dec 2022 | -$239.42M | -$60.98M(+2.5%) | -$245.73M(+1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$62.57M(+5.5%) | -$249.71M(-6.9%) |
| Jun 2022 | - | -$66.19M(-18.2%) | -$233.53M(-12.1%) |
| Mar 2022 | - | -$55.98M(+13.8%) | -$208.27M(-13.9%) |
| Dec 2021 | -$183.53M(-114.3%) | -$64.96M(-40.0%) | -$182.78M(-55.1%) |
| Sep 2021 | - | -$46.40M(-13.4%) | -$117.81M(-25.5%) |
| Jun 2021 | - | -$40.93M(-34.3%) | -$93.89M(-31.9%) |
| Mar 2021 | - | -$30.48M(-35.6%) | -$71.17M(-20.6%) |
| Dec 2020 | -$85.65M(-39.8%) | - | - |
| Sep 2020 | - | -$22.47M(-23.4%) | -$59.03M(-61.5%) |
| Jun 2020 | - | -$18.22M(+0.7%) | -$36.56M(-99.3%) |
| Mar 2020 | - | -$18.34M | -$18.34M |
| Dec 2019 | -$61.24M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual earnings before interest & taxes?
- What is the all-time high annual EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual EBIT year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
- What is the all-time high quarterly EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM earnings before interest & taxes?
- What is the all-time high TTM EBIT for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM EBIT year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual earnings before interest & taxes?
The current annual EBIT of RXRX is -$463.22M
What is the all-time high annual EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$61.24M
What is Recursion Pharmaceuticals, Inc. annual EBIT year-on-year change?
Over the past year, RXRX annual earnings before interest & taxes has changed by -$131.19M (-39.51%)
What is Recursion Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of RXRX is -$172.20M
What is the all-time high quarterly EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is -$18.22M
What is Recursion Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
Over the past year, RXRX quarterly earnings before interest & taxes has changed by -$73.85M (-75.08%)
What is Recursion Pharmaceuticals, Inc. TTM earnings before interest & taxes?
The current TTM EBIT of RXRX is -$723.57M
What is the all-time high TTM EBIT for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$18.34M
What is Recursion Pharmaceuticals, Inc. TTM EBIT year-on-year change?
Over the past year, RXRX TTM earnings before interest & taxes has changed by -$319.20M (-78.94%)